These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 33347998

  • 1. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
    Tsujimura T, Takahara M, Iida O, Soga Y, Katsuki T, Fujihara M, Kawasaki D, Kozuki A, Mano T.
    J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
    Ichihashi S, Shibata T, Fujimura N, Nagatomi S, Yamamoto H, Kyuragi R, Adachi A, Iwakoshi S, Bolstad F, Saeki K, Obayashi K, Kichikawa K.
    J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
    Ullery BW, Tran K, Itoga N, Casey K, Dalman RL, Lee JT.
    J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
    [Abstract] [Full Text] [Related]

  • 6. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K, Ullery BW, Kret MR, Lee JT.
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns).
    Horie K, Takahara M, Nakama T, Tanaka A, Tobita K, Hayakawa N, Mori S, Iwata Y, Suzuki K.
    J Endovasc Ther; 2024 Jun; 31(3):400-409. PubMed ID: 36146948
    [Abstract] [Full Text] [Related]

  • 9. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K, Takahara M, Iida O, Soga Y, Kawasaki D, Nanto S, Yokoi H, Matoba S, ZEPHYR Investigators.
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [Abstract] [Full Text] [Related]

  • 10. Viabahn Stent Graft for the Endovascular Treatment of Occlusive Lesions in the Femoropopliteal Artery: A Retrospective Cohort Study with 4-Year Follow-Up.
    Ni Q, Yang S, Xue G, Zhou Z, Zhang L, Ye M.
    Ann Vasc Surg; 2020 Jul; 66():573-579. PubMed ID: 31743785
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
    Stern JR, Tran K, Chandra V, Harris EJ, Lee JT.
    Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
    [Abstract] [Full Text] [Related]

  • 12. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
    Katsuki T, Takahara M, Soga Y, Okamoto S, Iida O, Fujihara M, Kawasaki D, Ando K.
    J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
    [Abstract] [Full Text] [Related]

  • 13. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
    Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, Schroeder H, Prem JT, Holden A, Popma J, Jaff MR, Diaz-Cartelle J, Müller-Hülsbeck S, IMPERIAL investigators.
    Lancet; 2018 Oct 27; 392(10157):1541-1551. PubMed ID: 30262332
    [Abstract] [Full Text] [Related]

  • 14. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions.
    Ohki T, Kichikawa K, Yokoi H, Uematsu M, Yamaoka T, Maeda K, Kanaoka Y.
    J Vasc Surg; 2017 Jul 27; 66(1):130-142.e1. PubMed ID: 28400218
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
    Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T, Zilver PTX Single-Arm Study Investigators.
    J Endovasc Ther; 2011 Oct 27; 18(5):613-23. PubMed ID: 21992630
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
    Fujihara M, Utsunomiya M, Higashimori A, Yokoi Y, Nakamura M.
    Heart Vessels; 2016 Feb 27; 31(2):152-7. PubMed ID: 25351136
    [Abstract] [Full Text] [Related]

  • 18. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery.
    Ohki T, Kichikawa K, Yokoi H, Iida O, Yamaoka T, Maeda K, Kanaoka Y.
    J Vasc Surg; 2021 Dec 27; 74(6):1958-1967.e2. PubMed ID: 34182032
    [Abstract] [Full Text] [Related]

  • 19. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
    Dake MD, Fanelli F, Lottes AE, O'Leary EE, Reichert H, Jiang X, Fu W, Iida O, Zen K, Schermerhorn M, Zeller T, Ansel GM.
    Cardiovasc Intervent Radiol; 2021 Feb 27; 44(2):196-206. PubMed ID: 33025243
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.